IMMATICS NV (IMTX) Stock Price, Quote, News and Overview
NASDAQ:IMTX - Nasdaq - NL0015285941 - Common Stock - Currency: USD
IMTX Quote, Performance and Key Statistics
NASDAQ:IMTX (6/6/2025, 8:00:02 PM)
5.97
+0.19 (+3.29%)
The current stock price of IMTX is 5.97 USD. In the past month the price increased by 37.56%. In the past year, price decreased by -54.64%.
IMTX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.48 | 335.32B | ||
| AMGN | AMGEN INC | 13.99 | 156.11B | ||
| GILD | GILEAD SCIENCES INC | 14.53 | 139.89B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 115.69B | ||
| REGN | REGENERON PHARMACEUTICALS | 11.13 | 53.25B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 39.23B | ||
| ARGX | ARGENX SE - ADR | 101.9 | 35.78B | ||
| ONC | BEONE MEDICINES LTD-ADR | 6.55 | 27.68B | ||
| BNTX | BIONTECH SE-ADR | N/A | 26.08B | ||
| NTRA | NATERA INC | N/A | 22.36B | ||
| BIIB | BIOGEN INC | 8.42 | 19.51B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 15.29B |
Related stock screener links
About IMTX
Company Profile
Immatics NV is a clinical stage biopharmaceutical company, which engages in the research and development of T cell receptor-based immunotherapies for the treatment of cancer. The company is headquartered in Tuebingen, Baden-Wuerttemberg and currently employs 297 full-time employees. The company went IPO on 2020-07-02. The firm is focused on the discovery and development of T-Cell eceptors with the goal of enabling a robust and specific T-Cell response against these targets. The firm develops targeted immunotherapies with an emphasis on treating solid tumors through two distinct therapeutic modalities: Adoptive Cell Therapies (ACT) and antibody-like TCR Bispecifics (TCER). Its wholly owned pipeline comprises of eight therapeutic programs, of which four are in clinical trials, including IMA201 (MAGEA4/8), IMA202 (MAGEA1) and ACTolog IMA 101 (Multi-target pilot trial) for solid cancers and IMA203 (PRAME) for hematological and solid cancers, as well as four are in preclinical development, including IMA204 (COL6A3) and IMA401 (Cancer testis antigen) for solid cancers, and ACTallo IMA301 (Cancer testis antigen) and IMA402 (Cancer testis antigen) for hematological and solid cancers.
Company Info
IMMATICS NV
Paul Ehrlich-Strasse 15
Tuebingen BADEN-WUERTTEMBERG 72076 DE
CEO: Harpreet Singh
Employees: 618
Phone: 4970715397700
IMMATICS NV / IMTX FAQ
What is the stock price of IMMATICS NV today?
The current stock price of IMTX is 5.97 USD. The price increased by 3.29% in the last trading session.
What is the ticker symbol for IMMATICS NV stock?
The exchange symbol of IMMATICS NV is IMTX and it is listed on the Nasdaq exchange.
On which exchange is IMTX stock listed?
IMTX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for IMMATICS NV stock?
14 analysts have analysed IMTX and the average price target is 14.45 USD. This implies a price increase of 142.04% is expected in the next year compared to the current price of 5.97. Check the IMMATICS NV stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is IMMATICS NV worth?
IMMATICS NV (IMTX) has a market capitalization of 725.65M USD. This makes IMTX a Small Cap stock.
How many employees does IMMATICS NV have?
IMMATICS NV (IMTX) currently has 618 employees.
What are the support and resistance levels for IMMATICS NV (IMTX) stock?
IMMATICS NV (IMTX) has a support level at 5.96 and a resistance level at 5.98. Check the full technical report for a detailed analysis of IMTX support and resistance levels.
Is IMMATICS NV (IMTX) expected to grow?
The Revenue of IMMATICS NV (IMTX) is expected to decline by -46.88% in the next year. Check the estimates tab for more information on the IMTX EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy IMMATICS NV (IMTX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of IMTX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of IMTX, evaluating the profitability, health, valuation and growth aspects
- IMMATICS NV (IMTX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- IMMATICS NV (IMTX) Sales and EPS estimates to see what analysts future expectations are.
- IMMATICS NV (IMTX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- IMMATICS NV (IMTX) Insider and Institutional Ownership to learn about the owners and their transactions.
- IMMATICS NV (IMTX) Stock Chart to make your own analysis
- IMMATICS NV (IMTX) Latest news and press-releases to stay up to date.
Does IMMATICS NV (IMTX) stock pay dividends?
IMTX does not pay a dividend.
When does IMMATICS NV (IMTX) report earnings?
IMMATICS NV (IMTX) will report earnings on 2025-08-11.
What is the Price/Earnings (PE) ratio of IMMATICS NV (IMTX)?
IMMATICS NV (IMTX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.17).
What is the Short Interest ratio of IMMATICS NV (IMTX) stock?
The outstanding short interest for IMMATICS NV (IMTX) is 6.34% of its float. Check the ownership tab for more information on the IMTX short interest.
IMTX Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to IMTX. When comparing the yearly performance of all stocks, IMTX is a bad performer in the overall market: 79.58% of all stocks are doing better.
IMTX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to IMTX. While IMTX seems to be doing ok healthwise, there are quite some concerns on its profitability.
IMTX Financial Highlights
Over the last trailing twelve months IMTX reported a non-GAAP Earnings per Share(EPS) of -0.17. The EPS increased by 84.54% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 9.76% | ||
| ROA | 2.19% | ||
| ROE | 2.65% | ||
| Debt/Equity | 0.02 |
IMTX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 87% to IMTX. The Buy consensus is the average rating of analysts ratings from 14 analysts.
For the next year, analysts expect an EPS growth of -975.84% and a revenue growth -46.88% for IMTX